ABCL · AbCellera Biologics Inc.
AI read · Good for ABCL
The AI's read
The higher target and unchanged bullish rating show the analyst sees more potential in AbCellera's shares. But the story gives no new sales, trial, or profit results, so this is a positive analyst view, not proof the business has improved.